New tool could guide surgery timing for tough liver cancer
NCT ID NCT07208526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 270 people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed right away. After initial chemotherapy (GOLP regimen), participants are split into three groups: one continues medication, one goes straight to surgery, and one uses a special evaluation system (TDTP-RECIST) to decide if surgery is best. The goal is to see which approach leads to longer survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONVERSION THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan hospital, Shanghai
Shanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New drug cocktails aim to stop bile duct cancer return after surgery
- New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
- Anti-Inflammatory drug may boost cancer therapy in bile duct cancer